Search results
Results from the WOW.Com Content Network
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment . The company was founded in 1998 and went public in 2004.
The subcutaneous injection of atezolizumab and hyaluronidase was evaluated in IMscin001 (NCT03735121), an open-label, multi-center, international, randomized trial in adults with locally advanced or metastatic non-small cell lung cancer who were not previously exposed to cancer immunotherapy and who had disease progression following treatment with platinum-based chemotherapy. [2]
Umbralisib was granted accelerated approval for medical use in the United States in February 2021. [ 2 ] [ 6 ] [ 7 ] However, due to concerns for increased long term side effects leading to inferior overall survival which led to increased FDA scrutiny in the form of an ODAC review, [ 8 ] it has been withdrawn from the US market.
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
For premium support please call: 800-290-4726 more ways to reach us
In 2019, Apple forked the operating system for their tablets away from the one the company uses in its handsets. iPad OS was born. iPad OS is the software you’ll find on all but the oldest iPad ...
A human recombinant hyaluronidase kit, Hyqvia, was approved for use in the European Union in May 2013, [25] and in the United States in September 2014. [26] [27] It is a dual vial unit with one vial of immune globulin infusion 10% (human) and one vial of recombinant human hyaluronidase. [12]
Etizolam is not authorized by the FDA for medical use in the U.S. As of March 2016, etizolam is a controlled substance in the following states: Alabama, [ 44 ] Arkansas, [ 45 ] Florida, [ 46 ] Georgia (as Schedule IV, whereas all other states listed here prohibit it as a Schedule I substance), Louisiana, Mississippi, [ 47 ] Texas, [ 48 ] South ...